A clinical case of successful treatment of a giant serous endometrial carcinoma imitating ovarian cancer

Cover Page

Cite item

Full Text

Abstract

Background: Giant tumors of the abdominal cavity, as a rule, occur in elderly patients with characteristic features and represent a serious problem in terms of choosing a radical method of therapy. Of particular difficulty are cases of giant serous endometrial cancer, requiring a differential diagnosis with ovarian cancer.

Clinical case description: A clinical case of giant serous endometrial cancer mimicking ovarian cancer in a 55-year-old woman is presented. The patient came to the oncology department with complaints of abdominal enlargement, difficulty breathing and bloody discharge from the genital tract. The examination revealed the following: a giant formation (40×65 cm), occupying the entire pelvic and the entire abdominal cavities, ascites, lesions of the retroperitoneal lymph nodes, and the greater omentum, an umbilical hernia. A chest CT showed multiple contrast-accumulating circular shadows of 3–13 mm (metastases). By the decision of the council, after the preliminary chemoembolization of both the uterine and ovarian arteries, a supravaginal amputation of the uterus with appendages was performed, along with the resection of the greater omentum, removal of the umbilical hernia with positioning a plastic mesh implant and excision of an excess skin flap. The histological examination of the intraoperative material made it possible to verify the diagnosis of a serous endometrial carcinoma with subtotal tumor necrosis, the myometrium invasion of more than a half of its thickness, with the egress to the perimetrium, metastatic lesions of both ovaries, the greater omentum, anterior abdominal wall. Stage T3b (FIGO IIIB). In the postoperative period, 6 courses of Paclitaxel / Carboplatin (AUC4-5) chemotherapy were carried out with a pronounced clinical effect. The patient was discharged in a satisfactory condition. The control PET-CT scan after the 6th chemotherapy course showed no pathology in the thoracic cavity, and no process progress in the abdominal cavity. Currently, the remission of the disease is 9 months.

Conclusion: An algorithm for the diagnostic measures aimed at making the correct diagnosis is presented, and the tactics of treating a patient with giant serous endometrial cancer is described.

About the authors

Aleksander I. Berishvili

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Author for correspondence.
Email: aberishvili@yandex.ru
SPIN-code: 1828-6147

M.D., Ph.D., Dr. Sci. (Med.), Professor

Russian Federation, 28, Orechovy boulevard, Moscow, 115682

Yuri V. Ivanov

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Email: ivanovkb83@yandex.ru
ORCID iD: 0000-0001-6209-4194
SPIN-code: 3240-4335

M.D., Ph.D., Dr. Sci. (Med.), Professor

Russian Federation, 28, Orechovy boulevard, Moscow, 115682

Dmitry P. Lebedev

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Email: lebedevdp@gmail.com
ORCID iD: 0000-0003-1551-3127
SPIN-code: 4770-5722
Russian Federation, 28, Orechovy boulevard, Moscow, 115682

Fedor G. Zabozlaev

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Email: fzab@mail.ru
ORCID iD: 0000-0002-7445-8319
SPIN-code: 3259-9332

M.D., Ph.D., Dr. Sci. (Med.)

Russian Federation, 28, Orechovy boulevard, Moscow, 115682

Edward V. Kravchenko

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Email: patan-st@mail.ru
Russian Federation, 28, Orechovy boulevard, Moscow, 115682

Tatiana V. Klypa

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Email: tvklypa@gmail.com
ORCID iD: 0000-0002-2732-967X
SPIN-code: 2349-8980

M.D., Ph.D., Dr. Sci. (Med.)

Russian Federation, 28, Orechovy boulevard, Moscow, 115682

Anna G. Kedrova

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies

Email: kedrova.anna@gmail.com
ORCID iD: 0000-0003-1031-9376
SPIN-code: 3184-9760

M.D., Ph.D., Dr. Sci. (Med.)

Russian Federation, 28, Orechovy boulevard, Moscow, 115682

References

  1. Charo LM, Plaxe SC. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019. F1000Res. 2019;8:F1000. Faculty Rev-849. doi: 10.12688/f1000research.17408.1
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551
  3. Miller D, Filiaci V, Fleming G, et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2012;125(3):771. doi: 10.1016/j.ygyno.2012.03.034
  4. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646. doi: 10.1038/sj.bjc.6603012
  5. Rungruang B, Olawaiye AB. Comprehensive surgical staging for endometrial cancer. Rev Obstet Gynecol. 2012; 5(1):28–34.
  6. Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 2016;21(10):1250–1259. doi: 10.1634/theoncologist.2016-0062
  7. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;36(20): 2044–2051. doi: 10.1200/JCO.2017.76.5966
  8. Shaeffer DT, Randall ME. Adjuvant radiotherapy in endometrial carcinoma. Oncologist. 2005;10(8):623–631. doi: 10.1634/theoncologist.10-8-623
  9. Le Gallo M, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem. 2014;60(1):98–110. doi: 10.1373/clinchem.2013.205740
  10. Lokich E, Kole M, Raker C, et al. Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens. Gynecol Oncol Rep. 2019;29:98–101. doi: 10.1016/j.gore.2019.04.005
  11. Schwab CL, Santin AD. Targeted therapy in the treatment of uterine serous carcinoma. Pharmacogenomics. 2015;16(2):97–99. doi: 10.2217/pgs.14.176
  12. Meng X, Laidler LL, Kosmacek EA, et al. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecol Oncol. 2013; 128(3):461–469. doi: 10.1016/j.ygyno.2012.11.004
  13. Houghton PJ. Everolimus. Clin Cancer Res. 2010;16: 1368–1372. doi: 10.1158/1078-0432.CCR-09-1314
  14. Barrington DA, Dilley SE, Smith HJ, Straughn JM. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecol. Oncol. 2019;153(2):381–384. doi: 10.1016/j.ygyno.2019.02.013

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. A patient’s photograph before the surgical intervention.

Download (1MB)
3. Fig. 2. Results of instrumental examination: а — computed tomography of abdominal organs; б — 3D reconstruction according to computed tomography, as a result of which the location of the tumor in relation to large vessels of the abdominal cavity was estimated.

Download (1MB)

Copyright (c) 2021 Berishvili A.I., Ivanov Y.V., Lebedev D.P., Zabozlaev F.G., Kravchenko E.V., Klypa T.V., Kedrova A.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies